X4 Pharmaceuticals, Inc.
XFOR
$3.73
-$0.14-3.62%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -10.54% | -93.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -10.54% | -93.15% | |||
| Cost of Revenue | 7.67% | -93.09% | |||
| Gross Profit | -14.15% | -93.16% | |||
| SG&A Expenses | -14.08% | -36.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.58% | -26.26% | |||
| Operating Income | 13.81% | -177.79% | |||
| Income Before Tax | -16.11% | -8,234.18% | |||
| Income Tax Expenses | -181.08% | 8.82% | |||
| Earnings from Continuing Operations | -15.83% | -9,228.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.83% | -9,228.01% | |||
| EBIT | 13.81% | -177.79% | |||
| EBITDA | 13.49% | -188.58% | |||
| EPS Basic | 80.16% | -8,528.16% | |||
| Normalized Basic EPS | 83.37% | -7,598.62% | |||
| EPS Diluted | 80.13% | -8,781.00% | |||
| Normalized Diluted EPS | 83.37% | -7,624.65% | |||
| Average Basic Shares Outstanding | 483.74% | 8.38% | |||
| Average Diluted Shares Outstanding | 483.74% | 7.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||